WO1999016881A1 - Proteine antigenique et acide nucleique codant pour elle - Google Patents
Proteine antigenique et acide nucleique codant pour elle Download PDFInfo
- Publication number
- WO1999016881A1 WO1999016881A1 PCT/JP1998/004326 JP9804326W WO9916881A1 WO 1999016881 A1 WO1999016881 A1 WO 1999016881A1 JP 9804326 W JP9804326 W JP 9804326W WO 9916881 A1 WO9916881 A1 WO 9916881A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- seq
- protein
- present
- antigen
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 141
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 139
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 139
- 108091007433 antigens Proteins 0.000 title claims abstract description 124
- 102000036639 antigens Human genes 0.000 title claims abstract description 119
- 108090000623 proteins and genes Proteins 0.000 title claims description 110
- 102000004169 proteins and genes Human genes 0.000 title claims description 78
- 241000222122 Candida albicans Species 0.000 claims abstract description 59
- 241000124008 Mammalia Species 0.000 claims abstract description 52
- 229940095731 candida albicans Drugs 0.000 claims abstract description 43
- 206010007134 Candida infections Diseases 0.000 claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 77
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 72
- 229920001184 polypeptide Polymers 0.000 claims description 70
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 61
- 150000001413 amino acids Chemical class 0.000 claims description 53
- 230000000890 antigenic effect Effects 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 33
- 239000013598 vector Substances 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 241000233866 Fungi Species 0.000 abstract description 17
- 238000011282 treatment Methods 0.000 abstract description 12
- 238000003745 diagnosis Methods 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 45
- 239000000427 antigen Substances 0.000 description 40
- 208000015181 infectious disease Diseases 0.000 description 33
- 238000000034 method Methods 0.000 description 31
- 210000002966 serum Anatomy 0.000 description 25
- 239000002299 complementary DNA Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 16
- 230000001032 anti-candidal effect Effects 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 13
- 208000026935 allergic disease Diseases 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 210000002421 cell wall Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 10
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 238000002649 immunization Methods 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 208000031888 Mycoses Diseases 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 108010092041 Lysine-tRNA Ligase Proteins 0.000 description 7
- 102000017737 Lysine-tRNA Ligase Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 206010017533 Fungal infection Diseases 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000002538 fungal effect Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 210000001938 protoplast Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 229920000057 Mannan Polymers 0.000 description 4
- 101100006827 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SAL1 gene Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000235070 Saccharomyces Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000941 radioactive substance Substances 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 239000007222 ypd medium Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 101150086780 EGD2 gene Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 2
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 2
- 101710113864 Heat shock protein 90 Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 101100058541 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BMH2 gene Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- -1 fatty acid esters Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- 101150101112 7 gene Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 101150108426 BMH2 gene Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 244000197813 Camelina sativa Species 0.000 description 1
- 101900217083 Candida albicans Triosephosphate isomerase Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101100403820 Methanopyrus kandleri (strain AV19 / DSM 6324 / JCM 9639 / NBRC 100938) nac gene Proteins 0.000 description 1
- 101100465000 Mus musculus Prag1 gene Proteins 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100459404 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) npc-1 gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 101900084120 Saccharomyces cerevisiae Triosephosphate isomerase Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- MCFVRESNTICQSJ-RJNTXXOISA-L calcium sorbate Chemical compound [Ca+2].C\C=C\C=C\C([O-])=O.C\C=C\C=C\C([O-])=O MCFVRESNTICQSJ-RJNTXXOISA-L 0.000 description 1
- 235000010244 calcium sorbate Nutrition 0.000 description 1
- 239000004303 calcium sorbate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- QMDUPVPMPVZZGK-UHFFFAOYSA-N n,n-dimethyloctadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[NH+](C)C QMDUPVPMPVZZGK-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 101150022630 prp5 gene Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940035670 tuftsin Drugs 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 108010082737 zymolyase Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
- C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/823—Lower fungi, e.g. mold
- Y10S530/824—Yeasts
Definitions
- the present invention relates to a Candida albicans antigen protein useful for the prevention, treatment, and diagnosis of fungal infections and allergic diseases, and a nucleic acid encoding the same. Further, the present invention relates to a vector comprising the nucleic acid, and a transformant transformed by the vector. Further, the present invention relates to a method for producing the antigen protein of the present invention, which comprises culturing such a transformant. Further, the present invention relates to a pharmaceutical composition and a diagnostic composition containing the antigenic protein or nucleic acid of the present invention. Background art
- Candida * Albicans is an indigenous human bacterium, but healthy individuals usually show resistance to infection with this bacterium and rarely cause systemic infections. However, this bacterium can cause partial infections in healthy individuals, and can cause vaginal candidiasis in women, especially in pregnant women.
- humans who have become immunocompromised due to receiving anticancer drugs to treat cancer such as leukemia, receiving immunosuppressive drugs accompanying organ transplantation, or having AIDS infection Can cause systemic infections, including the internal organs.
- the fungus is the most frequent allergen among fungi and is responsible for allergic diseases.
- most humans are immunized with Candida albicans, a resident bacterium, have antibodies against the components of Candida albicans, and have acquired cellular immunity.
- antigens are cell wall constituents, mainly polysaccharides such as mannan and glucan on the cell surface. Many conjugates with proteins.
- intracellular components such as enolase :, HSP90 (heat shock protein90), and phosphoglycerate kinase (Phosphoglycerate kinase) and antibodies to alcohol dehydrogenase (alcohol dehydrogenase) have been detected.
- Candida 'Candida fungi other than albicans such as Candida' tropicalis, Candida and C. glabrata, also mainly cause infections in immunocompromised hosts.
- Fungi other than Candida spp. Such as Aspergillus sp., Penici Ilium spp., And Alternaria spp., are widely present in the environment and are very familiar to mammals including humans. Being present.
- the cell growth form of these fungi is yeast-like or hyphal-like, their cell structures are basically similar, and the entire surface is surrounded by thick cell walls.
- the chemical structure of cell wall components differs to some extent depending on the type of fungus, it is mainly composed of polysaccharides such as mannan, glucan and chitin.
- cell membranes surrounded by cell walls, and components such as proteins in the cytoplasm are basically similar. Many of these fungi can cause infections in immunocompromised hosts or cause allergies.
- An object of the present invention is to provide a novel antigenic protein useful for treating and diagnosing fungal diseases such as Candida albicans. Further eyes of the present invention The object is to provide a nucleic acid encoding the antigen protein. It is a further object of the present invention to provide a vector containing the nucleic acid, and a transformant transformed with the vector. It is a further object of the present invention to provide a method for producing the antigen protein of the present invention, which comprises culturing such a transformant. It is a further object of the present invention to provide a pharmaceutical composition and a diagnostic composition containing the antigenic protein or nucleic acid of the present invention. Disclosure of the invention
- the present inventors have studied methods for imparting Candida albicans infection resistance to mammals susceptible to Candida albicans infection, such as mice and rats. As a result, it was revealed that Candida albicans cells can be used as an antigen to immunize these mammals with the adjuvant of incomplete Freund's adjuvant to achieve strong resistance and infection resistance. . And it was revealed that CD4-positive T cells play an important role in this infection resistance. Furthermore, the antiserum obtained from an immunized mammal that has acquired the above-mentioned infection resistance is surprisingly surprising to the fungal cell surface compared to, for example, factor serum No. 1 (manufactured by Jatron), which is a commercially available anti-candida serum. A low antibody titer was shown for the cell wall-derived components present in the cells, and a higher antibody titer was shown for the components derived from fungal protoplast cells from which the cell wall had been removed.
- factor serum No. 1 manufactured by Jatron
- Antigen proteins recognized by antisera were searched. That is, an expression library was prepared based on Candida albicans cDNA, and searched by immunoscreening. As a result, eight types of antigenic proteins were found as recombinant proteins of Escherichia coli, their DNAs were isolated, their nucleotide sequences were determined, and their amino acid sequences were determined from their nucleotide sequences, thereby completing the present invention. That is, the gist of the present invention is:
- an antigen protein characterized by being recognized by antisera derived from a mammal resistant to Candida albicans infection
- Candida albicans infection resistance which comprises culturing the transformant according to [5] under conditions capable of expressing an antigenic protein encoded by the nucleic acid according to [3].
- a method for producing an antigenic protein recognized by an antiserum derived from a sexual mammal comprises culturing the transformant according to [5] under conditions capable of expressing an antigenic protein encoded by the nucleic acid according to [3].
- a pharmaceutical composition comprising the antigen protein according to (1) or (2), or an antigen protein obtained by the production method according to (6);
- a diagnostic composition comprising the antigen protein according to any one of (1) or (2), or the antigen protein obtained by the production method according to (6).
- a diagnostic composition comprising the nucleic acid of [3]; [11] an antibody that specifically binds to the antigen protein of any of [1] or [2]; Or an antibody fragment; and
- FIG. 1 shows the results of subjecting a recombinant protein derived from the lysyl tRNA synthetase homolog gene and TPI homolog gene of C. albicans to SDS-polyacrylamide gel electrophoresis.
- Antigen protein of the present invention is antigen protein of the present invention
- the antigen protein of the present invention is a protein recognized by antiserum derived from a mammal resistant to Candida albicans infection.
- Candida albicans-resistant mammal refers to a mammal that has acquired infection resistance by immunizing with an antigen derived from Candida albicans, and has a lethal amount of Candida albicans cells (immune) before immunization. The number of cells that die within 10 days after internal infection) is a mammal that has not died.
- Such a mammal can be obtained, for example, as follows.
- mice For animals susceptible to Candida albicans infection, for example, mice such as C57BL / 6, BAL B / c, DB AZ2, and rats such as SP rague—Dawley, Wi star, etc., live Candida albicans cells as antigens
- a mixture using incomplete Freund's adjuvant (IFA) to induce cell-mediated immunity as an adjuvant is administered subcutaneously or intraperitoneally at least twice at an interval of 1 to 2 weeks for immunization.
- the animals immunized in this way and acquired resistance to infection are designated as Candida albicans resistant mammals.
- antiserum derived from a mammal resistant to Candida albicans infection is an antiserum obtained from a mammal resistant to Candida albicans infection.
- an antiserum for example, blood collected from a Candida or Albicans-resistant mammal 1 to 2 weeks after the final immunization can be used.
- Such an antiserum is preferably a mouse as a mammal, and more preferably a C 5 With 7 BL / 6, BAL BZ c or DB AZ 2, mixed for example with 1 x 1 0 5 ⁇ 1 XI 0 8 amino live cells and IFA this, at about 1 week intervals using the resulting mixture It is an antiserum that has been immunized twice or more and then obtained after one week to one month.
- the antiserum used in the present invention has a high antibody titer against cell membrane components of fungal cells and intracellular molecules.
- the commonly used anti-Candida antiserum is not derived from infection-resistant mammals, but has a high antibody titer against components of the surface cell wall, such as mannan and mannan protein. However, it is different from the antiserum in the present invention.
- Candida albicans cells that can be used in the present invention are not particularly limited, and include, for example, Candida albicans TIMM 168 strain, Candida albicans ATCC 1023 strain and the like.
- “recognized by antiserum” means binding to an antibody component contained in the antiserum, and is usually used for measuring this binding by immunoblotting ⁇ ELISA.
- the antigen can be detected and Z or quantified by immunological techniques such as immunoprecipitation.
- the binding between the antigen and the antibody is usually performed at 4 ° C to room temperature in an appropriate solution, in a gel, or on an antigen-immobilized plate.
- antigenic proteins are used as vaccine antigens in mammals to induce protective immunity against Candida albicans infections such as Candida albicans and other fungal infections, and to diagnose the presence or absence and progress of infections. It is useful as an antigen for It is also useful as an antigen for the prevention, treatment and diagnosis of allergic diseases caused by fungi such as Candida and Albicans.
- Candida albicans is an indigenous bacterium in humans, most human immune cells (lymphocytes, macrophages, etc.) release various cytokines from antigen proteins derived from Candida albicans and release immune cells. causes an immune response such as activation.
- the antigen protein of the present invention is useful as an antigen for releasing or activating effective immunomodulators such as interferon 7 and interleukin 4. You.
- the antigen protein of the present invention can be used as an antigenic component in individuals for in vivo diagnosis, for example, in inhalation provocation tests, skin tests, and mucous membrane tests of the nose and eyes.
- laboratory diagnostics for example, antigenicity in antigen-antibody reactions such as agglutination, sedimentation, neutralization, diagnostics using labeled antibody, histamine release test, lymphocyte blastogenesis test, leukocyte migration inhibition test, etc. Can also be used for ingredients o
- the antigen protein of the present invention is not particularly limited as long as it is a protein or polybeptide recognized by an antiserum derived from a mammal resistant to Candida albicans infection. Such a protein or polypeptide can be obtained, for example, by immunoscreening against a Candida albicans cDNA expression product using an antiserum derived from a mammal resistant to Candida albicans infection.
- protein means a main component of an organism, and indicates a protein consisting of a polybeptide chain.
- polypeptide as used herein means a plurality of amino acids bonded by peptide bonds, and the number of constituent amino acids is not particularly limited.
- polypeptide in the present specification may be either a simple polypeptide composed of only amino acids or a composite polypeptide containing a component other than amino acid.
- fusion protein is used herein, which means a protein or polypeptide to which some or all of two or more proteins are bound.
- antigenic protein of the present invention include, for example, the following polypeptides.
- A-1 a polypeptide having any one of the amino acid sequences set forth in SEQ ID NOs: 1 to 9,
- A-2) a polymer having an amino acid sequence in which one or more, for example, one or more amino acids have been deleted, substituted, inserted or added in any of the amino acid sequences shown in SEQ ID NOs: 1 to 9; Pseudo, (A-3) a polypeptide encoded by a nucleic acid having any of the base sequences represented by SEQ ID NOS: 10 to 18,
- A-4) a nucleotide sequence in which one or more, for example, one or more nucleotides are deleted, substituted, inserted or added in any of the nucleotide sequences shown in SEQ ID NOS: 10 to 18 A polypeptide encoded by a nucleic acid.
- the present invention also includes proteins that are immunologically equivalent to the antigen protein.
- each of the polypeptides consisting of the amino acid sequences represented by SEQ ID NOs: 1 to 9 can be obtained by immunoscreening using an antiserum derived from a mammal resistant to Candida albicans infection. It is derived from the cDNA library of TIMM1768 strain.
- an expression library using Escherichia coli as a host is used in the immunoscreening, the polypeptide is expressed as a simple polypeptide. Therefore, the antigen protein was screened using an antibody against the polypeptide moiety, except for the effect of the antibody on the sugar chains contained in anti-Candida serum.
- the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 1 in the Sequence Listing consists of 248 amino acids, and is composed of Saccharomyces cerevisiae triosephosphate isomerase (triosephosphate isomerase; T. Alber and G. Kawasaki, Journal of Molecular and Applied Genetics, Vol. 1, 419-434 (1982)).
- Saccharomyces cerevisiae triosephosphate isomerase triosephosphate isomerase
- T. Alber and G. Kawasaki Journal of Molecular and Applied Genetics, Vol. 1, 419-434 (1982)
- the N-terminal methionine has been eliminated. Therefore, at least the portion which can be easily used as an antigen protein is at least SEQ ID NO: It appears to be in the 2nd to 24th 8th region of 1.
- polypeptide shown in SEQ ID NO: 1 in the sequence listing is a full-length structure of Candida albicans triose phosphate isomerase.
- the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing consists of 132 amino acids, and is composed of lysyl-tRNA synthase of Saccharomyces cerevisiae (590 amino acids; M. irande and JP Walker, Journal of Biologic al Chemistry, Vol, 263, 18443-18451 (1988)) and a region near the N-terminus (amino acid numbers: 10 to 1337).
- polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 3 in the sequence listing consists of 548 amino acids, and the 260th to 546th portion of this polypeptide has a YCR0330 on chromosome 3 of Saccharomyces cerevisiae.
- C encoding a protein consisting of 870 amino acids; MR Red et al., Yeast, Vol. 7, 533-538 (1991)). Has homology.
- polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 4 in the sequence listing consists of 175 amino acids, and EGD2 of Saccharomyces' Celepiche (composed of 174 amino acids;. Johnston et al., Science, Vol. 265, 2077) -2082 (1994)).
- polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 5 in the sequence listing is composed of 88 amino acids, and the ATP synthase delta chain of Saccharomyces' Celepiche (comprising 244 amino acids; J. Velours et al., European Journal of Biochemistry, Vol. 170, 637-642 (1988)) and a region near the C-terminus (amino acid number: 158 to 242).
- polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 6 in the sequence listing consists of 264 amino acids, and is composed of Saccharomyces cerevisiae BMH2 (comprising 272 amino acids; GPH von Heusden et al., European Journal of Biochemistry, Vol. 229, 45-53 (1995)).
- polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 7 in the sequence listing is composed of 224 amino acids, and the liposome YL8 protein of Saccharomyces cerevisiae (consisting of 243 amino acids; K. izuta et al., Nucleic Acids Res., Vol. 20, 1011-1016 (1992)).
- polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 8 in the sequence listing consists of 115 amino acids, and the 46th to C-terminal portions of SEQ ID NO: 8 are YNL083w (49) of Saccharomyces cerevisiae. Consists of 4 amino acids; has homology with the 284th to 35th third part of A. Soler-Mira et al., East, Vol. 12, 485-491 (1996).
- Polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 9 in the sequence listing is a known HSP70SSB type polypeptide, and has been discovered as an antigen protein recognized by anti-Candida serum.
- the total length is 613 amino acids, and a polypeptide consisting of the 280th to C-terminal (333 amino acids) of SEQ ID NO: 9 has been obtained as an antigen protein [V. Maneu et al.. Yeast, 13, 677-681. (1997)].
- the present invention in the cDNA relating to the amino acid sequence shown in SEQ ID NO: 9 in the sequence listing, four types of cDNAs having a positive result of immunoscreening of the expressed product were obtained.
- the amino acid sequence shown in SEQ ID NO: 9 in the sequence listing from the 320th to the C-terminal (294 amino acids), from the 45th to the C-terminal (162 amino acids), from the 496th to the C-terminal (118 amino acids), which encodes the 5th to C-terminal (101 amino acids). Therefore, it is considered that C-terminal at least 100 amino acids in length is important for antigenic expression.
- polypeptides having about 100 to 294 amino acids including at least 100 amino acids on the C-terminal side, including the above four proteins, are included in the antigen protein of the present invention. That is, in the amino acid sequence represented by SEQ ID NO: 9 in the sequence listing of the present invention, a polypeptide obtained by removing 319 to 512 amino acids in length from the N-terminal is also included in the antigen protein of the present invention. You.
- the antigen protein of the present invention a polypeptide having an amino acid sequence in which one or more, for example, one or more amino acids have been deleted, substituted, inserted or added in each of the above polypeptides is also included.
- a plurality refers to several or more.
- the antigenic proteins shown in SEQ ID NO: 1 and SEQ ID NO: 2 are obtained as a fusion protein with a peptide containing a T7 fragment at the N-terminus, and are not related to such antigenicity.
- Proteins or polypeptides to which the above-mentioned peptide has been added are also included in the antigenic proteins of the present invention, but those in which the T7 fragment has been deleted are also included in the antigenic proteins of the present invention.
- a polypeptide in which about 319 to 512 amino acids have been deleted from the N-terminal side may also be deleted.
- polypeptides consisting of a part of the amino acid sequences shown in SEQ ID NOs: 1 to 9 in the sequence listing are also used in the present invention, as long as they are recognized by antisera derived from mammals resistant to Candida albicans infection. Included in antigen proteins. Furthermore, one or more amino acids, for example, one or more amino acids may be deleted, substituted, inserted, or added in an amino acid sequence consisting of a portion thereof, as long as the amino acid is recognized by an antiserum derived from a mammal resistant to Candida albicans infection. The polypeptide having the amino acid sequence described above is also included in the antigen protein of the present invention.
- antigenic proteins of the present invention include proteins and polypeptides obtained by adding a peptide irrelevant to antigenicity to the antigenic proteins of the present invention as described above.
- the polypeptide consisting of a part of the amino acid sequence shown in SEQ ID NOs: 1 to 9 in the Sequence Listing can be obtained by, for example, using an antigen protein consisting of the amino acid sequence shown in SEQ ID NOs: 1 to 9 in the Sequence Listing as a raw material. After cleavage by enzymatic digestion with a proteinase such as lysyl endopeptidease or trypsin, or after cleavage by chemical treatment with cyanogen bromide or the like, the peptide fragment having the desired antigenicity is converted into a protein fragment. It can be obtained by, for example, isolation and purification by a known method in purification.
- a proteinase such as lysyl endopeptidease or trypsin
- Techniques for deleting, substituting, inserting or adding one or more, for example, one or more amino acids in an amino acid sequence include molecular cloning: Laboratory Manual, 2nd edition (1989, Cold It is not difficult to use various genetic engineering techniques, such as those described in Spring Harbor Laboratory, edited by T. Mania Teis et al.
- the base sequences shown in SEQ ID NOs: 10 to 18 in the sequence listing are examples of nucleic acid sequences encoding the polypeptides consisting of the amino acid sequences shown in SEQ ID NOs: 1 to 9, respectively. Therefore, in the present invention, a protein or a polypeptide recognized by an antiserum derived from a Candida albicans-infected resistant mammal, which comprises the nucleotide sequence represented by SEQ ID NO: 10 to 18 in the sequence listing The polypeptide encoded by the nucleic acid is included in the antigen protein of the present invention.
- the nucleic acid is a cDNA that expresses an antigenic protein obtained by immunoscreening of an expression library, and the cDNA is composed of a full-length gene or a partial base sequence.
- the nucleotide sequences shown in SEQ ID NO: 10 and SEQ ID NO: 15 in the sequence listing are the full length of the antigen protein gene, and are shown in SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13
- the nucleotide sequences shown in SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18 are partial sequences of the antigen protein gene.
- the antigen protein derived from HSP70 SSB DNA encoded by the nucleic acid described in SEQ ID NO: 18 is the smallest antigen protein described above, for example, 51 of the amino acid sequence shown in SEQ ID NO: 9 in the sequence listing.
- the recombinant DNA encoding the highly antigenic portion is designed to contain the second base sequence of 580 to 882 of SEQ ID NO: 10 in the sequence listing. Is preferred.
- a polypeptide encoded by a nucleic acid having a base sequence in which a plurality of bases are deleted, substituted, inserted, or added is also included in the antigen protein of the present invention.
- a plurality refers to several or more o
- Candida albicans mutants related species (for example, Candida fungi such as Candida tropicalis), Saccharomyces, and proteins derived from fungi other than S. cerevisiae, Proteins or polypeptides having immunologically equivalent properties are also included in the antigenic protein of the present invention.
- the antigen of the present invention having any of the amino acid sequences shown in SEQ ID NOs: 1 to 9 although the amino acid sequence or the modification of the sugar chain or the like is different from the “protein having immunologically equivalent properties” in the present specification It means a protein or polypeptide recognized by an antibody contained in an antiserum derived from a mammal immunized with a protein.
- the antigen protein of the present invention may be modified into a derivative for the purpose of strengthening the specific binding between the antigen and the antibody.
- Alteration Examples of the method include pyridylethylation, reduction, alkylation, acylation, chemical coupling to an appropriate simple substance, mild formalin treatment, or guanidine hydrochloride treatment.
- Derivatives can be prepared by, for example, conjugation with PEG using the polyethylene glycol (PEG) method [Wie et al., Int. Arch. Allergy Appl. Immunol., Vol. 64, 84-99, (1981)]. May be.
- the nucleic acid of the present invention is a nucleic acid encoding an antigen protein recognized by an antiserum derived from a mammal resistant to Candida albicans infection.
- Such a nucleic acid can be obtained, for example, by preparing a Candida albicans cDNA expression library and performing immunoscreening with an antiserum derived from a Candida albicans-resistant mammal in the same manner as the antigen protein of the present invention. be able to. Further, a Candida albicans genomic library or a cDNA library was prepared, and the library was probed with an oligonucleotide presumed to encode a part of the amino acid sequence of the antigenic protein of the present invention. It can also be obtained by screening.
- the nucleic acid of the present invention can be used as a vaccine antigen gene in mammals to induce protective immunity against Candida albicans and other fungal infections such as Candida albicans, as well as Candida and Albicans. It is useful as an antigen gene for prevention, treatment and diagnosis of allergic diseases caused by fungi.
- nucleic acid of the present invention include, for example, the following nucleic acids.
- (B-1) a nucleic acid encoding a polypeptide having any of the amino acid sequences set forth in SEQ ID NOs: 1 to 9,
- (B-2) one or more, for example, one or more amino acids are deleted, substituted, inserted, or added in any of the amino acid sequences shown in SEQ ID NOs: 1 to 9
- (B-4) a nucleic acid having a base sequence in which one or more, for example, one or more bases have been deleted, substituted, inserted, or added in any of the base sequences shown in SEQ ID NOS: 10 to 18, ,
- (B-5) a nucleic acid that hybridizes to the nucleic acid according to any one of (B-1) to (B-4) or a nucleic acid complementary to the nucleic acid under stringent conditions.
- the nucleic acid may be either DNA or RNA.
- nucleotide sequences shown in SEQ ID NOs: 10 to 18 in the sequence listing are examples of nucleic acid sequences encoding the polypeptides consisting of the amino acid sequences shown in SEQ ID NOs: 1 to 9, respectively.
- nucleic acids It is known that one to six codons (combinations of three bases) that specify amino acids on a gene exist for each type of amino acid. Therefore, there may be many types of nucleic acids encoding a certain amino acid sequence, depending on the amino acid sequence. Nucleic acids are never stable in nature, and mutations in their base sequences are not uncommon. In some cases, a mutation that occurs in a nucleic acid does not change the amino acid sequence encoded therein (called a silent mutation), and a nucleic acid having such a mutation has a different amino acid sequence that encodes the same amino acid sequence as the nucleic acid before the mutation. It can be called a nucleic acid.
- nucleic acid encoding a specific amino acid sequence is isolated, many types of nucleic acids encoding the same amino acid sequence can be produced as the organism containing the nucleic acid is passaged. Sex cannot be denied. Furthermore, it is not difficult to artificially produce various kinds of nucleic acids encoding the same amino acid sequence by using various genetic engineering techniques.
- codons used on the original DNA that encodes the target protein are rarely used in the host.
- the expression level of the protein may be low.
- high expression of the target protein can be achieved by artificially converting codons into those frequently used in the host without changing the amino acid sequence coded. This is being done (for example, Japanese Patent Publication No. 7-1102146).
- nucleic acid encoding the polypeptide consisting of each of the amino acid sequences shown in SEQ ID NOs: 1 to 9 shown in (B-1) in this specification is represented by (B-3)
- the present invention is not limited to nucleic acids consisting of the nucleotide sequences shown in SEQ ID NOs: 10 to 18.
- each of the nucleotide sequences represented by SEQ ID NOS: 10 to 18 in the sequence listing includes 1
- a nucleic acid of the present invention includes a nucleic acid having a base sequence in which at least one, for example, one or more bases are deleted, substituted, inserted or added.
- the term “plurality” refers to several or more.
- nucleic acid that hybridizes under stringent conditions to a nucleic acid represented by any one of (B-1) to (B-4) or a nucleic acid complementary to the nucleic acid, wherein the nucleic acid is a Candida albiforce.
- the nucleic acid of the present invention also includes a nucleic acid encoding an antigen protein recognized by an antiserum derived from a mammal infected with a resistance to infection (ie, the nucleic acid of (B-5)). It is. Such a nucleic acid can be detected as follows.
- the probe used in (1) is a nucleic acid represented by (B-1) to (B-4) or a part of a nucleic acid complementary to the nucleic acid.
- nucleic acids include, for example, nucleic acids represented by (B-1) to (B-4), which are present in mutants of Candida albicans and related fungi (for example, Candida fungi such as Candida tropicalis).
- nucleic acid which can hybridize with a nucleic acid complementary to the nucleic acid under a stringent condition, and which encodes a protein having immunologically equivalent antigenicity and the like can be mentioned.
- nucleic acid of the present invention may be a nucleic acid encoding a polypeptide having any of the amino acid sequences shown in SEQ ID NOs: 1 to 9, or one of the amino acid sequences shown in SEQ ID NOs: 1 to 9 As described above, for example, in a nucleic acid encoding a polypeptide having an amino acid sequence in which one or more amino acids have been deleted, substituted, inserted, or added, the variant, allele, homologous gene, or codon degeneracy may be reduced.
- Associated nucleic acids are also included in the nucleic acids of the invention, as long as their expression is recognized by antisera from Candida albicans-resistant mammals.
- nucleic acids of the present invention include nucleic acids encoding antigen proteins recognized by antisera derived from mammals resistant to Candida albicans infection, such as the nucleic acids shown in (B-1) to (B-5). Nucleic acids that specifically bind are also included.
- the nucleic acid of the present invention may be labeled with a known fluorescent substance or radioactive substance. The nucleic acid can be used as a probe for detecting a Candida albicans antigen protein gene by hybridization or as a primer in a DNA amplification method using DNA polymerase.
- the vector of the present invention is a vector containing the nucleic acid of the present invention.
- a vector can stably maintain the nucleic acid of the present invention in a host such as Escherichia coli.
- the vector used for the construction of such a vector include pUC118, pWH5, pTV118, pSCREEN-1b, and the like.
- any vector into which the nucleic acid of the present invention can be inserted and can be expressed is used. Not limited. Alternatively, it can be used as a recombinant DNA for expression by connecting to an appropriate expression vector.
- the nucleic acid having the nucleotide sequence shown in SEQ ID NOS: 10 to 18 was ligated to pSCREEN-1b, introduced into E. coli as recombinant DNA for expression, and used in the present invention.
- the method for inserting the nucleic acid into the vector is not particularly limited, and a known method such as a method using T4 DNA ligase can be used.
- the transformant of the present invention has been transformed by the vector of the present invention.
- a transformant can be obtained by introducing the vector of the present invention into a host.
- bacteria such as Escherichia coli and Bacillus
- yeasts such as Saccharomyces cerevisiae
- fungi such as Aspergillus and Pichia pastoris
- animal cells such as insect cells, COS-7, and Ver0 cells
- Vector one as a method for introducing into a host for example, calcium phosphate method, CaC l 2 method, D EAE dextran method, include known methods such as electroporation Pauley Chillon method You.
- Such a transformant can be selected, for example, by using the selectable marker of the vector used as an indicator. Further, for example, the nucleic acid extracted from the transformant and the nucleic acid of the present invention can be specifically detected. Hybridization using a probe makes it possible to confirm that the desired nucleic acid has been introduced.
- Such a transformant can be used for preparing the nucleic acid of the present invention and for preparing the antigenic protein of the present invention.
- the method of the present invention for producing an antigen protein recognized by an antiserum derived from a Candida albicans-resistant mammal is capable of expressing the transformant of the present invention with an antigen protein encoded by the nucleic acid of the present invention. It is characterized by culturing under conditions.
- the culture conditions are not particularly limited. For example, they can be obtained using lambda phage vector— AS CREEN—1 and Phage Maker TM System Phage Pack Extract (both manufactured by Novagen) as vectors.
- the cells may be cultured in an LB medium containing ampicillin as a selective pressure, and the expression may be induced by IPTG (isopropyl monothio-D-galactoside) at an appropriate time.
- Transformants obtained using other vectors and hosts may be cultured in a medium under appropriate selection pressure under conditions suitable for protein expression. By culturing in this way, the desired protein is expressed.
- the expressed protein or polypeptide can be recovered and purified by a protein purification method known in the art.
- the presence or absence of antigenicity of the obtained protein or polypeptide can be confirmed by, for example, an immunological technique such as an immunoblotting method, an ELISA or an immunoprecipitation method.
- the antigen protein of the present invention may be produced from the transformant of the present invention obtained by using a genetic engineering technique, and may be a known protein from a Candida albicans culture. It may be obtained by a protein purification method.
- the pharmaceutical composition and the diagnostic composition of the present invention include 1) an antigen protein of the present invention or an antigen protein obtained by the production method of the present invention, and 2) a nucleic acid of the present invention. is there.
- composition and diagnostic composition containing the antigenic protein of the present invention or the antigenic protein obtained by the production method of the present invention
- the pharmaceutical composition and the diagnostic composition of the present invention include, in mammals, a vaccine for inducing protection and immunity against infection with Candida albicans and other Candida bacteria and other fungal infections, and the presence or absence of infection. And a diagnostic composition for judging the progress status. Further, the present invention includes compositions used for prevention, treatment and diagnosis of allergic diseases caused by fungi such as Candida albicans. In addition, since Candida albicans is an indigenous human bacterium, most human immune cells (lymphocytes, macrophages, etc.) release various cytokines against Candida albicans-derived antigenic proteins and activate immune cells. Cause an immune response such as That is, the pharmaceutical composition and the diagnostic composition of the present invention also include a composition for releasing or activating an effective immunomodulator such as interferon 7 and interlipin 4.
- an effective immunomodulator such as interferon 7 and interlipin 4.
- the composition for inducing protective immunity was a suspension or solution containing the adjuvant of the antigen protein of the present invention in order to obtain stronger, humoral, and Z or cellular immunity. It is generally used as a preparation.
- the adjuvant is usually administered together with the antigenic component, but may be given before or after administration of the antigenic component,
- Suitable adjuvants for vaccination of mammals include Freund's complete or incomplete adjuvants; aluminum hydroxide, alum Inorganic gels such as lysolecithin and dimethyloctadecyl ammonium bromide; surfactants such as dextran sulfate and poly IC; peptides such as muramyl peptides and tuftsin; monophos manufactured by Ribi Follipid A (MPL); includes but is not limited to the B subunit of cholera toxin.
- the antigen can be administered by incorporation into ribosomes or other microcarriers. Of course, it is also possible to use a mixture of several different antigen proteins.
- a composition for preventing, treating or diagnosing an allergic disease may be prepared by using the antigen protein of the present invention in the form of a suitable salt solution or suspension.
- polyethylene glycol phenol may be added.
- it may be a suspension or a solution containing the above-mentioned adjuvant.
- the adjuvant is usually administered with the antigen, but may be given before or after the antigen administration.
- Antigens can also be administered incorporated into ribosomes or other microcarriers.
- the pharmaceutical composition of the present invention may optionally contain various additives, and the dosage form may be various.
- additives include preparation additives for forming a desired dosage form.
- these additives include nutrients such as ascorbic acid, biotin, calcium pantothenate, and niacin; sodium metaphosphate, sodium phosphate (first, second and third salts), sodium pyrophosphate and the like.
- Preservatives such as calcium sorbate and benzoic acid; additives such as arabia gum, tragacanth, sodium alginate, mannite, sorbitol, lactose, fructose, soluble starch, amino acids, dextrose, sugar, honey, fatty acid esters and other additives Or diluents.
- the pharmaceutical composition of the present invention can be administered orally or parenterally.
- dosage forms suitable for oral administration such as powders, granules, pellets or tablets, coatings, capsules, solutions, syrups and the like;
- Formulations suitable for parenteral administration such as injections, drops, suppositories, eye drops, drops, and sprays, can be made.
- parenteral administration such as injections, drops, suppositories, eye drops, drops, and sprays
- the pharmaceutical composition of the present invention is used particularly as a vaccine, human serum albumin, gelatin, amino acids and the like at appropriate concentrations as stabilizers, and phenol and thimerosal at appropriate concentrations as preservatives may be added as necessary.
- the pharmaceutical composition may be used as a liquid preparation or may be used as a dry preparation by freeze-drying. The dry preparation may be used by suspending it in a suitable solvent such as distilled water for injection.
- the administration method of the pharmaceutical composition may be oral, transmucosal (nasal, vaginal, etc.), transdermal (subcutaneous or intradermal) or intravenous.
- a typical dose is, as protein amount, preferably in the range of 0.01 to 5.0 OmgZkg body weight, more preferably in the range of lg to 100 zgZkg body weight, but if necessary, administration The dose may be increased or the number of administrations may be increased.
- a diagnostic composition used in an individual for example, in an inhalation provocation test, a skin test, or a mucous membrane test of the nose and eyes, may be obtained by lyophilizing the antigen protein of the present invention or using an appropriate salt Examples thereof include solutions and suspensions, and polyethylene glycol or phenol may be added.
- the antigen protein of the present invention may be mixed with a mixture obtained by adding a surfactant such as sodium lauryl sulfate based on white cellulose to the base.
- a surfactant such as sodium lauryl sulfate based on white cellulose
- the pharmaceutical composition and the diagnostic composition of the present invention include a vaccine for inducing protective immunity against infection by Candida albicans and other Candida fungi and other fungal infections in mammals, and a Candida albicans. It can be used to prevent, treat and diagnose allergic diseases caused by fungi.
- a nucleic acid of the present invention may be expressed downstream of a suitable promoter so that the nucleic acid of the present invention can be expressed in mammalian cells. Rasmid may be used as is or in a retrovirus or adenovirus to form a suitable salt solution or suspension.
- the nucleic acid of the present invention may be incorporated into ribosomes or other microcarriers, or mixed with an appropriate polycationic lipid.
- nucleic acid a nucleic acid containing a chemical modification that can enhance the translocation into the cell or the stability in the cell may be used.
- chemical modification include derivatives such as phosphorothioate, phosphorodithioate, alkylphosphotriester, alkylphosphonate, and alkylphosphoamide.
- the method of administering the pharmaceutical composition of the present invention may be intramuscular, subcutaneous, intravenous, oral, rectal, transdermal, nasal, sublingual, intraperitoneal, or the like.
- a typical dosage is preferably in the range of 0.01 g to 1 O mg / kg body weight as the amount of nucleic acid, more preferably in the range of lg to 5 mg Z kg body weight, but the dosage may be increased as necessary. Or increase the number of doses.
- the antibody of the present invention is an antibody that specifically binds to the antigen protein of the present invention.
- antibodies include antibody fragments as long as they specifically bind to the antigen protein of the present invention.
- the antibody of the present invention can be obtained by a conventional method, and may be either a polyclonal antibody or a monoclonal antibody. Further, in the present invention, a single-chain antibody that specifically binds to the antigen protein of the present invention may be used.
- the antibody or antibody fragment can be used for detecting a fungus in an infection caused by Candida albicans or a related bacterium, and identifying an allergen in an allergic disease caused by Candida albicans or a related bacterium.
- the antibody or antibody fragment of the present invention When used for detecting a fungus in an infectious disease, identifying an allergen in an allergic disease, or the like, it may be labeled with a known fluorescent substance or radioactive substance. It can also be used for purification of the antigen protein of the present invention. In this case, for example, by immobilizing the antibody or antibody fragment of the present invention on a carrier or the like, the antigen protein of the present invention can be more easily purified.
- the nucleic acid that specifically binds to the nucleic acid encoding the antigen protein of the present invention may be obtained by a probe used for detecting the nucleic acid encoding the antigen protein of the present invention by hybridization or a DNA amplification method using DNA polymerase. It can be used as a primer for detection.
- the nucleic acid that specifically binds to the nucleic acid encoding the antigen protein of the present invention includes those that bind to either the sense side or antisense side of the nucleic acid encoding the antigen protein.
- the nucleic acid may be labeled with a known fluorescent substance or radioactive substance.
- Example 1 Induction of infection resistance and involvement of CD4-positive T cells in infection resistance
- the cells were cultured overnight with shaking in dextrose medium, and the cells were collected by centrifugation and washed with physiological saline. The resulting cells were suspended in 1 X 1 0 6, 1 X 1 0 7, 1 X 1 0 8 or Zm 1 become by Uni saline. An equal volume of IFA (incomplete Freund's adjuvant) was added to each suspension and mixed, and the mixture was subcutaneously inoculated into C57BL Z6 mice in an amount of 0.1 ml per mouse, and the mice were cultured with live Candida cells. Immunized. One week later, the same amount of live Candida cells prepared as above was subcutaneously inoculated in the same amount, and the mice were further immunized. Was.
- IFA incomplete Freund's adjuvant
- one mouse was immunized twice with 5 ⁇ 10 4 , 5 ⁇ 10 5 or 5 ⁇ 10 6 live Candida cells.
- physiological saline was used instead of the suspension of live Candida cells, and a mixture of the physiological saline and an equal amount of IFA was administered by subcutaneous inoculation twice at weekly intervals.
- mice and control mice were intravenously injected with 2.5 x 10 6 C. albicans TIMM 1768 cells obtained by culturing in Sabouraud's dextrose medium. To be infected. After infection, the mice were observed for life and death for 30 days. Table 1 shows the results.
- mice and immunized but no antibody New mice were prepared, and 1 ⁇ 10 6 C. albicans TI reader 0136 cells were similarly intravenously administered thereto. Seven days after the administration, the number of surviving C. albicans cells in the kidney was measured.
- the anti-CD4 antibody and anti-CD8 antibody were purified from ascites in which the hybridoma was grown by injecting the hybridoma into the peritoneal cavity of the scid mouse according to a conventional method. In addition, it was confirmed that each cell of the obtained antibody was removed by a flow cytometer (manufactured by Orso Diagnostics).
- Example 2 Collection and properties of sera from infection-resistant mammals, and preparation of various absorbed sera
- CFA complete Freund's adjuvant
- Example 2-1 The properties of the anti-candida serum obtained in Example 2-1) were examined.
- C. albicans cell wall fraction (CW), cytoplasmic fraction (HSS) and cell membrane fraction (LSP) were prepared as antigen components.
- the LSP was suspended in 140 ml of physiological saline, sonicated, and further heat-treated in a boiling water bath for 5 minutes to be sterilized to obtain an LSP antigen solution containing a membrane protein and the like.
- CW was subjected to ultrasonic treatment and heat treatment to obtain a CW antigen solution.
- the HSS antigen solution was used as is for HSS.
- the protein concentration of the LSP antigen solution obtained as described above was 2.3 mg / ml, the protein concentration of the HS S antigen solution was 3.5 mgZml, and the protein concentration of the CW antigen solution was 2.1 mgZml.
- the CW antigen solution, LSP antigen solution, and HSS antigen solution obtained as antigen components were diluted with PBS so that the protein concentration of each became 10 g1, and then 50 zl was added to the Immo 'module (Nunc). Were added and left at 4 ° C., and each immuno and module was coated with each antigen.
- the coated immuno module was subjected to blocking treatment with a PBS solution containing 1% by weight of bovine serum albumin. Then, add 50 1 of anti-candida serum or control serum diluted 60-fold to Imno module, incubate at 37 ° C for 1 hour, and add peroxidase-labeled anti-mouse IgG antibody (diluted 2000-fold) and 37 ° C. Incubated for 1 hour. After incubation, the plate was washed with PBS, and then a substrate solution was added. After 15 minutes, the absorbance at 405 nm was measured. The higher the absorbance, the greater the amount of antibody that recognizes the antigen, that is, the higher the antibody titer against the antigen. The results are shown in Table 2.
- the above control serum was prepared by subcutaneously inoculating three times at weekly intervals with a mixture of physiological saline and an equal amount of CFA using physiological saline instead of viable bacteria. Prepared
- anti-Candida serum has the highest antibody titer against HSS, but also has an antibody titer against LSP .
- Antibody titers to CW were low.
- cDNA was synthesized from poly (A) + RNA5 zg. After ligating the synthesized cDNA with lambda phage vector Yuichi; ISCREEN-1 (Novagen), in vitro packaging was performed using Phage Maker TM System AgePack Extract (Novagen), and c A DNA library was constructed.
- Phage clones expressing a protein that reacts with antiserum from C. albicans live cell immunization were detected by immunoscreening.
- Phage vector In the cDNA library created using ISCREEN-1, the cDNA is derived from the fusion protein with the peptide containing the T7 fragment sequence or the translation start codon in the cDNA. Expressed as a starting polypeptide.
- the cDNA library was inoculated into the host E. coli BL21 (DE3) pLysE strain, mixed with top agarose (LB medium containing 0.7% by weight agarose), and then 2XYT (1.6% by weight pactotryptone, 1% by weight). % Yeast extract, 0.5% by weight of NaCl) on a plate, and incubate at 37 ° C for 6 hours. Lark was formed. A nylon membrane [Hyb on d-N, manufactured by Amersham Co.] was overlaid on the resulting plaques, allowed to stand overnight at 4 ° C, and then kept at 37 ° C for 4 hours.
- the membrane After removing the membrane from the plate and washing with PBST (composition: 10 OmM NaCl, 10 mM phosphate buffer- ⁇ H7.5, 0.1% Tween 20) for 10 minutes, the membrane is removed. Blocking was performed by immersing in an appropriate amount of Block Ace (Dainippon Pharmaceutical Co., Ltd.). After leaving overnight at room temperature, the membrane was incubated with the anti-Candida serum (diluted 1: 500) prepared in Example 2-1) for 3 hours at room temperature. After incubation, the plate was washed, and then incubated with a peroxidase-labeled anti-mouse IgG antibody (diluted 1:00) for 1 hour at room temperature. After incubation, the plate was washed, and then luminescent by SuperSignal Substrate Western Blotting (Pierce) to detect phage plaque that reacts with anti-Candida serum.
- PBST composition: 10 OmM NaCl, 10 mM phosphate buffer- ⁇ H7.5, 0.1%
- the clone 2 is a novel gene having homology with triosephosphate isomerase of Saccharomyces cerevisiae (S. cerevisiae). Had. In addition, one clone each of a novel gene having homology with S. cerevisiae lysyl tRNA synthetase and DNA 98 of chromosome 3 of S. cerevisiae was also present. These cDNAs contained a part of each gene, and it was revealed that an antigenic determinant reacting with antiserum was present in this region.
- the nucleotide sequences of the novel genes s. Cerevisiae triosephosphate isomerase homologue gene, S.
- cerepiserisyl-tRNA synthetase homologue gene and DNA 98 homologue gene of S. cerepis chromosome 3 are shown in the sequence listing, respectively.
- SEQ ID NO: 10 SEQ ID NO: 11
- SEQ ID NO: 12 SEQ ID NO: 12
- SEQ ID NO: 3 SEQ ID NO: 3 in the sequence listing. Encodes a polypeptide having the amino acid sequence shown in FIG.
- imnoscreening of the C. albicans antigen protein was performed from the cDNA library described in 1) above. That is, a solution was prepared by mixing anti-candida serum, HSS and CW at a ratio of 1: 1: 1 (vZv / v), and this was used as an absorbed antiserum.
- antigen molecules were screened in the same manner as in Example 3-2).
- the antiserum used was a 500-fold dilution of the absorbed antiserum. Phage plaques that react with this antiserum were further cloned.
- one clone contained almost the entire length of a novel gene homologous to the EGD2 gene of S. cerevisiae, and one clone contained ATP synthase delta chain (ATP synthase delta chain). chain) and a part of a novel gene having homology.
- the obtained base sequence information is shown in SEQ ID NO: 13 and SEQ ID NO: 14 in the sequence listing, respectively.
- this base sequence encodes a polypeptide having the amino acid sequence shown in SEQ ID NO: 4 and SEQ ID NO: 5 in the sequence listing, respectively.
- HSP 7 The 0 SSB type antigen was found to have an antigenic determinant that reacts with antiserum in the C-terminal 118 amino acid region.
- the nucleotide sequence of the HSP70SSB type gene encoding the longest 294 amino acids, and the amino acid sequence deduced from the nucleotide sequence are as shown in SEQ ID NO: 18 and SEQ ID NO: 9, respectively.
- nucleotide sequences of these novel genes are SEQ ID NO: 15 in the sequence listing, respectively.
- SEQ ID NO: 16 and SEQ ID NO: 17 based on this nucleotide sequence, these genes are represented by the amino acid sequences shown in SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8 in the sequence listing, respectively. Polypeptides are included.
- Example 4 Production of antigenic protein recognized by C. albicans-resistant mammal
- the cDNAs obtained in Examples 3-2) and 3-3) were expressed as fusion proteins, except for genes having homology with YNL083W of S. cerepiche.
- the gene having homology with YNL083W expressed the polypeptide from the initiation codon (ATG) in cDNA.
- An example showing the expression of the fusion protein has homology with triosephosphate isomerase (TPI).
- TPI triosephosphate isomerase
- a plasmid containing a gene having homology with TPI obtained in Example 3-2) and a plasmid containing a gene having homology with lysyl-tRNA synthetase were respectively transformed into Escherichia coli BL21 (DE 3) It was transformed into pLysS to obtain a transformant. These transformants were inoculated into LB medium containing ampicillin and cultured at 37 ° C for 3.5 hours. I PTG (isopropyl-l-thio-D-galactoside) was added to a final concentration of ImM, and the culture was continued for another 2.5 hours.
- I PTG isopropyl-l-thio-D-galactoside
- the cells were suspended in 301 1 ⁇ SDS sample buffer. After heat treatment at 100 ° C for 5 minutes, the mixture was centrifuged, and a part of the supernatant was subjected to SDS-polyacrylamide gel (12.5% gel) electrophoresis to confirm the expression of the polypeptide.
- the predicted molecular weight of the expressed fusion protein is 63 kDa for the TPI homolog (27 kDa for the TPI homolog + 36 kDa for the T7 tag region) and 50 kDa for the lysyl-tRNA synthetase homolog (lysyl-tRNA synthetase homolog 14 kDa + T7 Region (36 kDa).
- FIG. 1 revealed that these fusion proteins were expressed as polypeptides having the expected molecular weight.
- the sample in lane 1 in FIG. 1 is the polypeptide obtained before the induction of the expression of the transformant into which the lysyl-tRNA synthetase homolog gene was introduced (before IPTG addition), and the sample in lane 2 was the one after the induction (after IPTG addition). It is.
- the sample in lane 3 is the polypeptide obtained before the induction of the transformant into which the TPI homolog gene was introduced, and the sample in lane 4 is the polypeptide obtained after the induction.
- the antigen protein of the present invention is an antigen recognized by an antiserum derived from a mammal resistant to Candida albicans infection, and is useful for the treatment and diagnosis of Candida albicans infection. It is for. Further, the nucleic acid of the present invention encodes the antigen protein of the present invention, and is useful for treatment and diagnosis of Candida albicans infection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98944256A EP1026245A4 (en) | 1997-10-01 | 1998-09-28 | ANTIGENIC PROTEIN AND THE NUCLEIC ACID CODING THEREOF |
US09/509,744 US7070793B1 (en) | 1997-10-01 | 1998-09-28 | Antigen protein and nucleic acid coding for said protein |
US11/119,769 US20050276821A1 (en) | 1997-10-01 | 2005-05-03 | Antigen protein and nucleic acid coding for said protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9269087A JPH11103862A (ja) | 1997-10-01 | 1997-10-01 | 抗原タンパク質及び該タンパク質をコードする核酸 |
JP9/269087 | 1997-10-01 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/119,769 Division US20050276821A1 (en) | 1997-10-01 | 2005-05-03 | Antigen protein and nucleic acid coding for said protein |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999016881A1 true WO1999016881A1 (fr) | 1999-04-08 |
Family
ID=17467496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/004326 WO1999016881A1 (fr) | 1997-10-01 | 1998-09-28 | Proteine antigenique et acide nucleique codant pour elle |
Country Status (6)
Country | Link |
---|---|
US (2) | US7070793B1 (ja) |
EP (1) | EP1026245A4 (ja) |
JP (1) | JPH11103862A (ja) |
KR (1) | KR100567606B1 (ja) |
CN (1) | CN1280620A (ja) |
WO (1) | WO1999016881A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008109833A2 (en) * | 2007-03-07 | 2008-09-12 | University Of Florida Research Foundation, Inc. | Polynucleotides and polypeptides identified by iviat screening and methods of use |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6916626B1 (en) * | 2001-04-25 | 2005-07-12 | Rockeby Biomed Ltd. | Detection of Candida |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996036707A1 (en) * | 1995-05-16 | 1996-11-21 | Universita' Degli Studi Di Roma 'la Sapienza' | CANDIDA HEAT SHOCK PROTEIN, cDNA AND USES THEREOF |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753888A (en) * | 1986-04-09 | 1988-06-28 | Bionostics, Inc. | Multiple control standard for blood analysis |
GB8915019D0 (en) * | 1989-06-30 | 1989-08-23 | Matthews Ruth C | Medicaments |
CA2251593A1 (en) * | 1996-04-11 | 1997-10-16 | Mitotix, Inc. | Assays and reagents for identifying anti-fungal agents, and uses related thereto |
JPH10234379A (ja) * | 1997-02-27 | 1998-09-08 | Takara Shuzo Co Ltd | 真菌抗原及びその製造方法 |
-
1997
- 1997-10-01 JP JP9269087A patent/JPH11103862A/ja active Pending
-
1998
- 1998-09-28 WO PCT/JP1998/004326 patent/WO1999016881A1/ja not_active Application Discontinuation
- 1998-09-28 EP EP98944256A patent/EP1026245A4/en not_active Withdrawn
- 1998-09-28 KR KR1020007003572A patent/KR100567606B1/ko not_active IP Right Cessation
- 1998-09-28 CN CN98811595A patent/CN1280620A/zh active Pending
- 1998-09-28 US US09/509,744 patent/US7070793B1/en not_active Expired - Fee Related
-
2005
- 2005-05-03 US US11/119,769 patent/US20050276821A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996036707A1 (en) * | 1995-05-16 | 1996-11-21 | Universita' Degli Studi Di Roma 'la Sapienza' | CANDIDA HEAT SHOCK PROTEIN, cDNA AND USES THEREOF |
Non-Patent Citations (9)
Title |
---|
EROLES P, ET AL.: "CLONING OF A DNA FRAGMENT ENCODING PART OF A 70-KDA HEAT SHOCK PROTEIN OF CANDIDA ALBICANS", FEMS MICROBIOLOGY LETTERS, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 128, 1 January 1995 (1995-01-01), GB, pages 95 - 100, XP002917384, ISSN: 0378-1097, DOI: 10.1016/0378-1097(95)00089-N * |
GIL-NAVARRO I, ET AL.: "THE GLYCOLYTIC ENZYME GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE OF CANDIDA ALBICANS IS A SURFACE ANTIGEN", JOURNAL OF BACTERIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 179, no. 16, 1 January 1997 (1997-01-01), US, pages 4992 - 4999, XP002917386, ISSN: 0021-9193 * |
GOMEZ M J, ET AL.: "PURIFICATION AND BIOCHEMICAL CHARACTERIZATION OF A 65-KILODALTON MANNOPROTEIN (MP65), A MAIN TARGET OF ANTI-CANDIDA CELL-MEDIATED IMMUNE RESPONSES IN HUMANS", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 64, no. 07, 1 July 1996 (1996-07-01), US, pages 2577 - 2584, XP002917387, ISSN: 0019-9567 * |
MANEU V, ET AL.: "MOLECULAR CLONING OF A CANDIDA ALBICANS GENE (SSB1) CODING FOR A PROTEIN RELATED TO THE HSP70 FAMILY", YEAST, JOHN WILEY & SONS LTD., GB, vol. 13, 1 January 1997 (1997-01-01), GB, pages 677 - 681, XP002917385, ISSN: 0749-503X, DOI: 10.1002/(SICI)1097-0061(19970615)13:7<677::AID-YEA131>3.3.CO;2-Y * |
See also references of EP1026245A4 * |
SEPULVEDA P, ET AL.: "EVIDENCE FOR THE PRESENCE OF COLLAGENOUS DOMAINS IN CANDIDA ALBICANS CELL SURFACE PROTEINS", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 63, no. 06, 1 June 1995 (1995-06-01), US, pages 2173 - 2179, XP002917388, ISSN: 0019-9567 * |
SHEN H-D, ET AL.: "CHARACTERIZATION OF A MONOCLONAL ANTIBODY (RJ5) AGAINST THE IMMUNODOMINANT 41-KD ANTIGEN OF CANDIDA ALBICANS", INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, BASEL, CH, vol. 96, no. 02, 1 January 1991 (1991-01-01), CH, pages 142 - 148, XP002917389, ISSN: 0020-5915 * |
SHEN H-D, ET AL.: "THE 40-KILODALTON ALLERGEN OF CANDIDA ALBICANS IS AN ALCOHOL DEHYDROGENASE: MOLECULAR CLONING AND IMMUNOLOGICAL ANALYSIS USING MONOCLONAL ANTIBODIES", CLINICAL & EXPERIMENTAL ALLERGY : JOURNAL OF THE BRITISH SOCIETY FOR ALLERGY AND CLINICAL IMMUNOLOGY, WILEY INTERSCIENCE, UK, vol. 21, no. 06, 1 January 1991 (1991-01-01), UK, pages 675 - 682, XP002917390, ISSN: 0954-7894 * |
TRINEL P-A, ET AL.: "ISOLATION AND PRELIMINARY CHARACTERIZATION OF THE 14- TO 18- KILODALTON CANDIDA ALBICANS ANTIGEN AS A PHOSPHOLIPOMANNAN CONTAINING BETA-1,2-LINKED OLIGOMANNOSIDES", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 61, no. 10, 1 October 1993 (1993-10-01), US, pages 4398 - 4408, XP002918168, ISSN: 0019-9567 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008109833A2 (en) * | 2007-03-07 | 2008-09-12 | University Of Florida Research Foundation, Inc. | Polynucleotides and polypeptides identified by iviat screening and methods of use |
WO2008109833A3 (en) * | 2007-03-07 | 2008-12-18 | Univ Florida | Polynucleotides and polypeptides identified by iviat screening and methods of use |
Also Published As
Publication number | Publication date |
---|---|
US20050276821A1 (en) | 2005-12-15 |
US7070793B1 (en) | 2006-07-04 |
KR20010030880A (ko) | 2001-04-16 |
EP1026245A1 (en) | 2000-08-09 |
JPH11103862A (ja) | 1999-04-20 |
KR100567606B1 (ko) | 2006-04-04 |
EP1026245A4 (en) | 2005-03-30 |
CN1280620A (zh) | 2001-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7438916B2 (en) | Therapeutic target for protozoal diseases | |
Ziegelbauer et al. | Organization of two invariant surface glycoproteins in the surface coat of Trypanosoma brucei | |
Helbig et al. | Serological differentiation between cystic and alveolar echinococcosis by use of recombinant larval antigens | |
JP2002510494A (ja) | Mycobacteriumtuberculosis抗原の融合タンパク質およびその使用 | |
EP0429816A1 (en) | Vaccine composition with non-immunosuppresive T-cell epitope component | |
US7491405B2 (en) | Antigenic protein originating in Malassezia | |
US20040219165A1 (en) | Streptococcus pneumoniae antigens | |
KR20010082217A (ko) | 당뇨병의 치료 및 예방을 위한 키모킨 수용체 펩티드 백신 | |
US9556244B2 (en) | Vaccination of animals to elicit a protective immune response against tick infestations and tick-borne pathogen transmission | |
US6406883B1 (en) | Lmb gene of Streptococcus agalactiae | |
EP1141305B1 (en) | Chimeric gene encoding the antigenic determinants of four proteins of l. infantum | |
EP1037997A1 (en) | Lmb gene of streptococcus agalactiae | |
WO1999016881A1 (fr) | Proteine antigenique et acide nucleique codant pour elle | |
JP2002516662A (ja) | N−末端コリン結合プロテインa切端形のアミノ酸を含むポリペプチド、それに由来するワクチンおよびその使用 | |
AU2001271935B2 (en) | Multiple antigenic peptides immunogenic against streptococcus pneumoniae | |
EP1240328B1 (en) | Antigenic protein lppq of mycoplasma mycoides subsp. mycoides sc., its preparation and use | |
JP2005021166A (ja) | 抗原タンパク質及び該タンパク質をコードする核酸 | |
JP3983246B2 (ja) | マラセチア由来の抗原性蛋白質 | |
AU2001271935A1 (en) | Multiple antigenic peptides immunogenic against streptococcus pneumoniae | |
KR20180130217A (ko) | GnRH가 삽입된 STF2 재조합 단백질 및 이의 용도 | |
JP4044605B2 (ja) | マラセチア由来の抗原性蛋白質 | |
JP3613577B2 (ja) | 豚回虫(Ascarissuum)感染幼虫の16kDa抗原、それをコードする核酸分子及びそれらの利用 | |
JPH11206379A (ja) | マラセチア由来抗原性ポリペプチド | |
JPH11262392A (ja) | 新規MurE | |
Frosch | Serological differentiation between cystic and alveolar echinococcosis by use of recombinant larval antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98811595.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09509744 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007003572 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998944256 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998944256 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007003572 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007003572 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998944256 Country of ref document: EP |